<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Mol Sci</journal-id><journal-id journal-id-type="iso-abbrev">Int J Mol Sci</journal-id><journal-id journal-id-type="pmc-domain-id">808</journal-id><journal-id journal-id-type="pmc-domain">ijms</journal-id><journal-id journal-id-type="publisher-id">ijms</journal-id><journal-title-group><journal-title>International Journal of Molecular Sciences</journal-title></journal-title-group><issn pub-type="epub">1422-0067</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10055970</article-id><article-id pub-id-type="pmcid-ver">PMC10055970.1</article-id><article-id pub-id-type="pmcaid">10055970</article-id><article-id pub-id-type="pmcaiid">10055970</article-id><article-id pub-id-type="pmid">36982660</article-id><article-id pub-id-type="doi">10.3390/ijms24065583</article-id><article-id pub-id-type="publisher-id">ijms-24-05583</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Chromatin Remodeling Enzyme Cluster Predicts Prognosis and Clinical Benefit of Therapeutic Strategy in Breast Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-4508-4394</contrib-id><name name-style="western"><surname>Kuo</surname><given-names initials="CY">Chia-Yu</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#8211; original draft</role><xref rid="af1-ijms-24-05583" ref-type="aff">1</xref><xref rid="af2-ijms-24-05583" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-4082-1909</contrib-id><name name-style="western"><surname>Moi</surname><given-names initials="SH">Sin-Hua</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Software" vocab-term-identifier="https://credit.niso.org/contributor-roles/software/">Software</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><xref rid="af3-ijms-24-05583" ref-type="aff">3</xref><xref rid="af4-ijms-24-05583" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6030-9702</contrib-id><name name-style="western"><surname>Hou</surname><given-names initials="MF">Ming-Feng</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/">Methodology</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Resources" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><xref rid="af1-ijms-24-05583" ref-type="aff">1</xref><xref rid="af5-ijms-24-05583" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-6852-575X</contrib-id><name name-style="western"><surname>Luo</surname><given-names initials="CW">Chi-Wen</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Validation" vocab-term-identifier="https://credit.niso.org/contributor-roles/validation/">Validation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><xref rid="af1-ijms-24-05583" ref-type="aff">1</xref><xref rid="af6-ijms-24-05583" ref-type="aff">6</xref><xref rid="c1-ijms-24-05583" ref-type="corresp">*</xref><xref rid="fn1-ijms-24-05583" ref-type="author-notes">&#8224;</xref></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-2039-7570</contrib-id><name name-style="western"><surname>Pan</surname><given-names initials="MR">Mei-Ren</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#8211; review &amp; editing</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Funding acquisition" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/">Funding acquisition</role><xref rid="af3-ijms-24-05583" ref-type="aff">3</xref><xref rid="af7-ijms-24-05583" ref-type="aff">7</xref><xref rid="af8-ijms-24-05583" ref-type="aff">8</xref><xref rid="c1-ijms-24-05583" ref-type="corresp">*</xref><xref rid="fn1-ijms-24-05583" ref-type="author-notes">&#8224;</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Samsonova</surname><given-names initials="MG">Maria G.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-ijms-24-05583"><label>1</label>Division of Breast Oncology and Surgery, Department of Surgery, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan</aff><aff id="af2-ijms-24-05583"><label>2</label>Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan</aff><aff id="af3-ijms-24-05583"><label>3</label>Graduate Institute of Clinical Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan</aff><aff id="af4-ijms-24-05583"><label>4</label>Research Center for Precision Environmental Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan</aff><aff id="af5-ijms-24-05583"><label>5</label>Department of Biomedical Science and Environmental Biology, College of Life Science, Kaohsiung Medical University, Kaohsiung 807, Taiwan</aff><aff id="af6-ijms-24-05583"><label>6</label>Department of Cosmetic Science and Institute of Cosmetic Science, Chia Nan University of Pharmacy and Science, Tainan 717, Taiwan</aff><aff id="af7-ijms-24-05583"><label>7</label>Center for Cancer Research, Kaohsiung Medical University Hospital, Kaohsiung 807, Taiwan</aff><aff id="af8-ijms-24-05583"><label>8</label>Drug Development and Value Creation Research Center, Kaohsiung Medical University, Kaohsiung 807, Taiwan</aff><author-notes><corresp id="c1-ijms-24-05583"><label>*</label>Correspondence: <email>cwlo0623@gmail.com</email> (C.-W.L.); <email>mrpan@cc.kmu.edu.tw</email> (M.-R.P.); Tel.: +886-7-3121101 (ext. 2260) (C.-W.L.); +886-7-3121101 (ext. 5092-34) (M.-R.P.); Fax: +886-7-3165011 (C.-W.L.); +886-7-3218309 (M.-R.P.)</corresp><fn id="fn1-ijms-24-05583"><label>&#8224;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>15</day><month>3</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>3</month><year>2023</year></pub-date><volume>24</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">432204</issue-id><elocation-id>5583</elocation-id><history><date date-type="received"><day>23</day><month>1</month><year>2023</year></date><date date-type="rev-recd"><day>09</day><month>3</month><year>2023</year></date><date date-type="accepted"><day>12</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>15</day><month>03</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>30</day><month>03</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-03-30 16:10:12.397"><day>30</day><month>03</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2023 by the authors.</copyright-statement><copyright-year>2023</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="ijms-24-05583.pdf"/><abstract><p>The treatment provided for breast cancer depends on the expression of hormone receptors, human epidermal growth factor receptor-2 (HER2), and cancer staging. Surgical intervention, along with chemotherapy or radiation therapy, is the mainstay of treatment. Currently, precision medicine has led to personalized treatment using reliable biomarkers for the heterogeneity of breast cancer. Recent studies have shown that epigenetic modifications contribute to tumorigenesis through alterations in the expression of tumor suppressor genes. Our aim was to investigate the role of epigenetic modifications in genes involved in breast cancer. A total of 486 patients from The Cancer Genome Atlas Pan-cancer BRCA project were enrolled in our study. Hierarchical agglomerative clustering analysis further divided the 31 candidate genes into 2 clusters according to the optimal number. Kaplan&#8211;Meier plots showed worse progression-free survival (PFS) in the high-risk group of gene cluster 1 (GC1). In addition, the high-risk group showed worse PFS in GC1 with lymph node invasion, which also presented a trend of better PFS when chemotherapy was combined with radiotherapy than when chemotherapy was administered alone. In conclusion, we developed a novel panel using hierarchical clustering that high-risk groups of GC1 may be promising predictive biomarkers in the clinical treatment of patients with breast cancer.</p></abstract><kwd-group><kwd>chromatin remodeling enzyme</kwd><kwd>epigenetic modification</kwd><kwd>chemotherapy</kwd><kwd>radiotherapy</kwd><kwd>hierarchical clustering</kwd></kwd-group><funding-group><award-group><funding-source>Kaohsiung Medical University Hospital</funding-source><award-id>KMHK-DK(C)111003</award-id><award-id>KMUH-DK-109001</award-id><award-id>KMUH110-0T04</award-id><award-id>KMUH111-1R34</award-id></award-group><award-group><funding-source>National Science and Technology Council, Taiwan</funding-source><award-id>111-2320-B-037-030</award-id><award-id>111-2628-B-037-008</award-id><award-id>110-2320-B-037-006</award-id><award-id>111-2321-B-037-002</award-id><award-id>111-2320-B-037-030</award-id><award-id>110-2321-B-037-002</award-id><award-id>109-2314-B-037-019</award-id><award-id>109-2314-B-037-132-</award-id><award-id>109-2314-B-037-036-MY3</award-id></award-group><funding-statement>This research was funded by the following grants: (1) KMHK-DK(C)111003, KMUH-DK-109001, KMUH110-0T04, and KMUH111-1R34 from the Kaohsiung Medical University Hospital; (2) 111-2320-B-037-030, 111-2628-B-037-008, 110-2320-B-037-006, 111-2321-B-037-002, 111-2320-B-037-030, 110-2321-B-037-002, 109-2314-B-037-019, 109-2314-B-037-132-, and 109-2314-B-037-036-MY3 from the National Science and Technology Council, Taiwan. The APC was funded by 109-2314-B-037-036-MY3. </funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-ijms-24-05583"><title>1. Introduction</title><p>Breast cancer is the most prevalent cancer globally, with 2.26 million new cases diagnosed in 2020 [<xref rid="B1-ijms-24-05583" ref-type="bibr">1</xref>]. Breast cancer treatment includes surgery, chemotherapy, radiotherapy, and targeted therapy, which are comprehensively administered according to tumor size, lymph node status, and the expression of hormone receptors and human epidermal growth factor receptor-2 (HER2). For non-metastatic breast cancer, which at the time of diagnosis accounts for approximately 90% of patients, the treatment goals are tumor elimination and recurrence prevention [<xref rid="B2-ijms-24-05583" ref-type="bibr">2</xref>].</p><p>Systemic treatment for non-metastatic breast cancer is based on molecular subtypes. For patients with hormone receptor-positive breast cancer, standard endocrine therapy is administered for 5&#8211;10 years, according to menopausal status [<xref rid="B3-ijms-24-05583" ref-type="bibr">3</xref>]. HER2-targeted antibodies are effective in preventing recurrence and increasing overall survival in patients with HER2-positive breast cancer [<xref rid="B4-ijms-24-05583" ref-type="bibr">4</xref>]. Recently, several emerging antibody-drug conjugates have been approved by the U.S. Food and Drug Administration (FDA) and applied to breast cancer with HER2-overexpression. It has the advantage of delivering selective drugs to specific antigen-presenting cells, thereby minimizing toxicity to normal cells [<xref rid="B5-ijms-24-05583" ref-type="bibr">5</xref>]. For patients who are lymph node positive, HER2-positive, or have triple-negative breast cancer (TNBC) and a tumor size of &gt;1 cm, adjuvant anthracycline with cyclophosphamide and taxane-based chemotherapy is the backbone of treatment [<xref rid="B6-ijms-24-05583" ref-type="bibr">6</xref>]. The neoadjuvant chemotherapy setting is applied to some patients with locally advanced breast cancer to facilitate breast conservation during surgery and can provide important prognostic information about the response to treatment, particularly in HER2-positive breast cancer and TNBC [<xref rid="B7-ijms-24-05583" ref-type="bibr">7</xref>].</p><p>Clinically, prognostic factors can predict the population of at-risk patients, while predictive factors can identify a certain group that benefits from treatment. The strongest prognostic factors for breast cancer include tumor size, axillary lymph node involvement, histological grade, hormone receptor status, and age at diagnosis. The proportion of distant metastatic disease in breast carcinoma in situ was &lt;1% at 10 years of age. The 5-year overall survival rates of stage I hormone receptor-positive breast cancer, HER2-positive breast cancer, and TNBC are &gt;99%, &gt;94%, and &gt;85%, respectively [<xref rid="B8-ijms-24-05583" ref-type="bibr">8</xref>]. As predictive factors for breast cancer, estrogen receptor (ER) modulators can predict the likelihood of response to hormone therapy, and HER2/neu can predict the value of monoclonal antibodies, such as trastuzumab, pertuzumab, and neratinib [<xref rid="B9-ijms-24-05583" ref-type="bibr">9</xref>,<xref rid="B10-ijms-24-05583" ref-type="bibr">10</xref>]. However, regarding adjuvant chemotherapy and radiotherapy, there is still a lack of powerful biological hallmarks to discern whether treatment will be beneficial.</p><p>Currently, oncologists use molecular genomic profiling tests to establish precision medicine that can help personalize treatment, avoid over- or under-treatment, and maximize the outcomes for all subtypes of breast cancers. The following are several commercially available modalities of genomic assays that help clinicians decide on systemic therapy for early invasive breast cancer unrelated to the National Comprehensive Cancer Network, including Oncotype DX [<xref rid="B11-ijms-24-05583" ref-type="bibr">11</xref>], MammaPrint [<xref rid="B12-ijms-24-05583" ref-type="bibr">12</xref>], Prosigna [<xref rid="B13-ijms-24-05583" ref-type="bibr">13</xref>], EndoPredict [<xref rid="B14-ijms-24-05583" ref-type="bibr">14</xref>], and breast cancer index (BCI) [<xref rid="B15-ijms-24-05583" ref-type="bibr">15</xref>]. Multigene assays provide useful information, especially for patients with breast cancer who are equivocal for adjuvant therapy plans based on traditional immunohistochemical staining markers and clinical features. Notably, only a few genes are shared between the prognostic signatures, most of which differ. These genes do not include those involved in epigenetic modifications [<xref rid="B16-ijms-24-05583" ref-type="bibr">16</xref>]. In fact, there is discordance between these molecular prognostic assays; the preliminary phase III OPTIMA trial found that approximately 60% of patients were categorized into different risk groups [<xref rid="B17-ijms-24-05583" ref-type="bibr">17</xref>]. Moreover, ideal prognostic and predictive parameters for HER2-positive or TNBC are still lacking. Although distant recurrence can be calculated using basic clinical data, there was approximately a 20% risk of distant recurrence in patients in the low-risk group who did not receive adjuvant chemotherapy [<xref rid="B18-ijms-24-05583" ref-type="bibr">18</xref>]. Thus, developing a promising prognostic or predictive assay not only determines the benefits of chemotherapy and radiation therapy but also provides information on effective new drugs.</p><p>To date, researchers have investigated the relationship between epigenetic alterations and tumorigenesis. Recent studies have shown that epigenetic modifications are important in human breast cancer [<xref rid="B19-ijms-24-05583" ref-type="bibr">19</xref>,<xref rid="B20-ijms-24-05583" ref-type="bibr">20</xref>]. This process contributes to carcinogenesis by activating oncogenes and silencing tumor suppressor genes, thereby driving tumor growth and invasion [<xref rid="B20-ijms-24-05583" ref-type="bibr">20</xref>,<xref rid="B21-ijms-24-05583" ref-type="bibr">21</xref>]. As epigenetic modifications have been established, epigenetic-associated biomarkers may potentially serve as predictive or prognostic targets for the treatment of breast cancer [<xref rid="B22-ijms-24-05583" ref-type="bibr">22</xref>]. HDAC (Histone Deacetylases) and DNMT (DNA Methyltransferases) are epigenetic modifiers that regulate gene expression by altering chromatin structure [<xref rid="B23-ijms-24-05583" ref-type="bibr">23</xref>]. PRDM (PR/SET Domain) and PRMT (Protein Arginine Methyltransferase) families are transcriptional regulators that control gene expression by modifying histones and other proteins [<xref rid="B24-ijms-24-05583" ref-type="bibr">24</xref>]. Aberrant expression of these genes has been linked to the development and progression of breast cancer [<xref rid="B19-ijms-24-05583" ref-type="bibr">19</xref>]. Elevated levels of HDAC and DNMT have been associated with poor prognosis and resistance to chemotherapy and radiotherapy in breast cancer patients [<xref rid="B25-ijms-24-05583" ref-type="bibr">25</xref>]. On the other hand, decreased expression of PRDM and PRMT genes has been linked to poor prognosis and resistance to therapy [<xref rid="B24-ijms-24-05583" ref-type="bibr">24</xref>].</p><p>It is thought that changes in the expression levels of these genes alter the expression of critical genes involved in cell cycle regulation, DNA damage repair, and apoptosis. These alterations may affect the sensitivity of cancer cells to chemotherapy and radiotherapy and contribute to the development of resistance. However, the mechanism behind the association of these genes with breast cancer patient outcomes and response to therapy is complex and not fully understood. In the past decade, the direction of cancer treatment is from a &#8220;one-size-fits-all&#8221; approach turn into focusing on the precision medicine based on genomic variants [<xref rid="B26-ijms-24-05583" ref-type="bibr">26</xref>]. Therefore, we focused on common, well-known 5 proteins of DNMT family, 3 proteins of HDAC family, 15 proteins of PRDM family, and 8 proteins of PRMT family to discover an effective prognostic or predictive factor focusing on epigenetic processing of breast cancer in chemotherapy and radiotherapy settings using hierarchical agglomerative clustering analysis.</p></sec><sec sec-type="results" id="sec2-ijms-24-05583"><title>2. Results</title><sec id="sec2dot1-ijms-24-05583"><title>2.1. Baseline Characteristics</title><p>A total of 486 patients were included in this study. <xref rid="ijms-24-05583-t001" ref-type="table">Table 1</xref> shows the baseline characteristics of the study groups. The mean age of the patients was 55.9 years old and 68% were aged &gt;50 years. Among all the patients, 106 (22%) had TNBC and 380 (78%) had non-TNBC. A total of 261 patients (54%) presented with lymph node invasion. According to the eighth edition of the AJCC TNM system, 300 patients (62%) had pathological stage II disease, 87 (18%) had stage I disease, and 99 (20%) had stage III disease. Of the patients, 305 (63%), 386 (79%), and 253 (52%) received radiotherapy, chemotherapy, and a combination of the two, respectively. In total, 29 (6.0%) of the patients died, and disease progression was observed in 45 (9.3%) patients.</p></sec><sec id="sec2dot2-ijms-24-05583"><title>2.2. Hierarchical Clustering Analysis</title><p>The mRNA expression of the 31 candidate genes in the study population is shown in <xref rid="ijms-24-05583-t002" ref-type="table">Table 2</xref> and normalized using a heatmap (<xref rid="ijms-24-05583-f001" ref-type="fig">Figure 1</xref>). The median and range of each gene were calculated and compared with those of normal tissue. High and low expression of each gene are represented with a red-to-green color bar among the total 486 patients in the TNBC and non-TNBC groups. <xref rid="ijms-24-05583-f002" ref-type="fig">Figure 2</xref> shows a heatmap of the correlations among the 31 candidate genes in all study populations. A high-intensity positive correlation (blue) was observed between <italic toggle="yes">DNMT3B/DNMT3A, HDAC2/DNMT3A, PRDM2/PRDM10, PRDM4/PRDM10, PRDM8/PRDM1, PRMT10/PRDM10, PRMT10/PRDM2</italic>, and <italic toggle="yes">PRMT7/PRMT1</italic>. A strong negative correlation (red) was observed between <italic toggle="yes">PRMT1/PRDM10, PRMT1/PRDM2, PRMT1/PRDM5, PRMT7/PRDM10,</italic> and <italic toggle="yes">PRMT10/PRMT1</italic>. <xref rid="ijms-24-05583-f003" ref-type="fig">Figure 3</xref> shows the results of the hierarchical clustering analysis. According to the silhouette index, the optimal number of clusters was two (<xref rid="ijms-24-05583-f003" ref-type="fig">Figure 3</xref>A). A dendrogram of the target genes is shown in <xref rid="ijms-24-05583-f003" ref-type="fig">Figure 3</xref>B. All 31 target genes were assigned to 2 gene clusters according to the optimal number of clusters, and are illustrated in a cluster plot in <xref rid="ijms-24-05583-f003" ref-type="fig">Figure 3</xref>C.</p></sec><sec id="sec2dot3-ijms-24-05583"><title>2.3. Two Clusters According to the Optimal Number in Analysis</title><p>According to mRNA expression levels, the target genes were distributed into 2 groups, named gene clusters 1 and 2 (GC1/2). GC1 contained 20 genes, including <italic toggle="yes">DNMT1, DNMT2, DNMT3A, DNMT3B, DNMT3L, HDAC1, HDAC2, HDAC3, PRDM7, PRDM9, PRDM12, PRDM13, PRDM14, PRDM15, PRMT1, PRMT2, PRMT5, PRMT6, PRMT7</italic>, and <italic toggle="yes">PRMT8</italic>. GC2 contained 11 genes: <italic toggle="yes">PRDM1, PRDM2, PRDM4, PRDM5, PRDM6, PRDM8, PRDM10, PRDM11, PRDM16, PRMT3</italic>, and <italic toggle="yes">PRMT10</italic>. Risk estimation subgroups according to overall patient characteristics, lymph node invasion status, and treatment were further analyzed.</p></sec><sec id="sec2dot4-ijms-24-05583"><title>2.4. Higher mRNA Expression of Target Genes in High-Risk Groups</title><p>The high-risk subgroups in GC1 and GC2 revealed higher mRNA expression of almost all target genes, as shown in <xref rid="ijms-24-05583-t003" ref-type="table">Table 3</xref> and <xref rid="app1-ijms-24-05583" ref-type="app">Table S1</xref>, with significant differences (<italic toggle="yes">p</italic> &lt; 0.05), except for <italic toggle="yes">HDAC2, PRDM13, PRMT2, PRMT5, PRMT6</italic>, and <italic toggle="yes">PRDM11</italic>. In GC1, <italic toggle="yes">DNMT1</italic>, <italic toggle="yes">DNMT2, DNMT3A, DNMT3B, HDAC1, HDAC2, HDAC3, PRDM12, PRDM13, PRDM15, PRMT1, PRMT2</italic>, and <italic toggle="yes">PRMT5</italic> showed positive values in the high-risk subgroup, whereas <italic toggle="yes">DNMT3L, PRDM7, PRDM9, PRDM14, PRMT7</italic>, and <italic toggle="yes">PRMT8</italic> showed negative median values. In GC2, <italic toggle="yes">PRDM1, PRDM4, PRDM6</italic>, and <italic toggle="yes">PRMT3</italic> had positive median values in the high-risk subgroup, whereas <italic toggle="yes">PRDM2, PRDM5, PRDM8, PRDM10, PRDM11, PRDM16</italic>, and <italic toggle="yes">PRMT10</italic> had negative median values.</p></sec><sec id="sec2dot5-ijms-24-05583"><title>2.5. High- and Low-Risk Groups Clinical Manifestation</title><p>The distributions of the baseline characteristics according to hierarchical clusters are summarized in <xref rid="app1-ijms-24-05583" ref-type="app">Table S2</xref>. The distribution of TNBC was significantly different between the low- and high-risk groups for both GCs (<italic toggle="yes">p</italic> &lt; 0.001). There were no significant differences in lymph node invasion, stage, or radiotherapy between the low- and high-risk groups within the two GCs. More than 90% of high-risk patients in GC1 received chemotherapy, with a significant difference (<italic toggle="yes">p</italic> &lt; 0.001). Progressive disease was more frequent in the high-risk group of GC1 compared with the low-risk group (16 [16.5%] vs. 29 [7.5%], <italic toggle="yes">p</italic> = 0.006).</p></sec><sec id="sec2dot6-ijms-24-05583"><title>2.6. Progression-Free Survival Is Lower in the High-Risk Group of GC1</title><p>The Kaplan&#8211;Meier plot illustrating the 10-year PFS is shown in <xref rid="ijms-24-05583-f004" ref-type="fig">Figure 4</xref>. The patients were further divided into low- and high-risk subgroups in both gene clusters according to the risk estimation analysis. The results showed significant differences between the low- and high-risk groups in GC1 (<italic toggle="yes">p</italic> = 0.009), with a lower PFS in the high-risk group. However, no significant differences were observed in GC2 (<italic toggle="yes">p</italic> = 0.543). In addition, the high-risk GC1 group with lymph node invasion showed worse PFS than the low-risk group (<italic toggle="yes">p</italic> = 0.003), as illustrated in <xref rid="ijms-24-05583-f005" ref-type="fig">Figure 5</xref>. The estimated risk subgroup of GC1 revealed a worse PFS at high risk of chemotherapy alone (<italic toggle="yes">p</italic> = 0.018). Interestingly, there was a trend toward better PFS in the high-risk subgroup of GC1 in the chemotherapy combined with radiotherapy setting, but the difference was not significant (<italic toggle="yes">p</italic> = 0.241) (<xref rid="ijms-24-05583-f006" ref-type="fig">Figure 6</xref>). Additionally, chemotherapy with radiotherapy seemed to have a better PFS in the high-risk GC1 group than in the low-risk group, although the difference was not significant (<italic toggle="yes">p</italic> = 0.214) (<xref rid="app1-ijms-24-05583" ref-type="app">Figure S1</xref>).</p></sec><sec id="sec2dot7-ijms-24-05583"><title>2.7. mRNA Expression and Progression-Free Survival Analysis of GC1 High-Risk Group Target Genes According to TNBC and Non-TNBC Subgroups</title><p>The boxplot of the 20 target genes of the high-risk group in GC1 demonstrated significant differences in mRNA expression in the TNBC and non-TNBC groups, except for <italic toggle="yes">HDAC3</italic>, <italic toggle="yes">PRDM14</italic>, <italic toggle="yes">PRDM9</italic>, and <italic toggle="yes">PRMT6</italic> (<xref rid="app1-ijms-24-05583" ref-type="app">Figure S2</xref>). PFS was inferior in the high-risk group of GC1 in the TNBC subgroup analysis, although the difference was not significant (<italic toggle="yes">p</italic> = 0.061) (<xref rid="app1-ijms-24-05583" ref-type="app">Figure S3</xref>). Regarding lymph node status, there was a trend for worse PFS in the high-risk group for GC1 in TNBC with lymph node invasion (<xref rid="app1-ijms-24-05583" ref-type="app">Figure S4</xref>). Combined chemotherapy with radiotherapy seemed to result in better PFS in the TNBC subgroup with high-risk GC1 genes, as seen in the lymph node invasion analysis (<xref rid="app1-ijms-24-05583" ref-type="app">Figures S5&#8211;S8</xref>).</p></sec></sec><sec sec-type="discussion" id="sec3-ijms-24-05583"><title>3. Discussion</title><p>Breast cancer is a complex and multifactorial disease and the most common cancer in women worldwide [<xref rid="B27-ijms-24-05583" ref-type="bibr">27</xref>]. Currently, its diagnosis relies on analysis of clinical manifestations, imaging scans, and immunohistopathological examinations. Among all breast cancer subtypes, TNBC has a poor prognosis and high metastatic ability owing to its heterogeneity [<xref rid="B28-ijms-24-05583" ref-type="bibr">28</xref>]. Conventional systemic chemotherapy remains the mainstay of treatment. Radiotherapy is reserved for breast conservative surgery or post-mastectomy high-risk patients as a local, regional control. Recently, some targeted therapies and the immune checkpoint inhibitors were developed for advanced TNBC treatment [<xref rid="B29-ijms-24-05583" ref-type="bibr">29</xref>,<xref rid="B30-ijms-24-05583" ref-type="bibr">30</xref>]. However, not all TNBC patients respond to these treatments [<xref rid="B31-ijms-24-05583" ref-type="bibr">31</xref>]. Therefore, it still needs to find more precise treatments for individuals.</p><p>In the present study, a serial comprehensive analysis was conducted based on hierarchical clustering results. Thirty-one genes were divided into two clusters, thereby fulfilling the optimal number. We found that the high-risk group in GC1 had a higher proportion of TNBCs than the low-risk group. Moreover, patients in the high-risk subgroup of GC1 displayed a significantly lower PFS than those in the low-risk subgroup (<italic toggle="yes">p</italic> = 0.009). Another interesting finding was that combining chemotherapy with radiotherapy might result in a better survival rate in the high-risk subgroup of GC1. Hence, the panel of high-risk gene expression in GC1 may play a role as a promising predictive index and may also be effective in predicting treatment response to chemotherapy combined with radiotherapy in patients with TNBC. The risk estimation effects of GC1 maintained a consistent threshold in the TNBC and TNBC-LN-positive subgroups. Although no significant differences were found, the high-risk subgroup was more likely to achieve a poor PFS than the low-risk subgroup. The marginal effects of statistical significance may be because of the restricted sample size.</p><p>Epigenetic processes play important roles in carcinogenesis. The most well-known and comprehensive study of epigenetic mechanisms involves DNA methylation. Alterations in DNA methylation can lead to the development of cancer. Previous study indicated that <italic toggle="yes">DNMT1</italic>, <italic toggle="yes">DNMT3A</italic>, and <italic toggle="yes">DNMT3B</italic> are upregulated in breast tumor tissues compared with normal breast tissues [<xref rid="B32-ijms-24-05583" ref-type="bibr">32</xref>]. In addition, higher expression of <italic toggle="yes">DNMT1</italic> and <italic toggle="yes">DNMT3A</italic> was found in TNBC than in other breast cancer subtypes. Consistent with these findings, we found that the target genes were associated with epigenetic processing.</p><p>One of the key mechanisms involved in the regulation of histone modification is histone acetylation and deacetylation by <italic toggle="yes">HAT</italic> and <italic toggle="yes">HDAC</italic>, respectively. Several studies have identified deregulation of HDAC, particularly in breast cancer. Previous study found that <italic toggle="yes">HDAC1</italic> and <italic toggle="yes">HDAC3</italic> were upregulated in <italic toggle="yes">E2F1</italic> and <italic toggle="yes">E2F4</italic>, which are responsible for the downregulation of <italic toggle="yes">ARH1</italic>, a maternally imprinted tumor suppressor gene [<xref rid="B33-ijms-24-05583" ref-type="bibr">33</xref>]. Another comparative study demonstrated that global hypoacetylation of H4 was observed in the progression from normal epithelium to ductal carcinoma in situ to invasive ductal carcinoma [<xref rid="B34-ijms-24-05583" ref-type="bibr">34</xref>]. However, the abovementioned studies only focused on analyzing genes or proteins from one of the chromatin-modifying enzymes individually, which were different to this study.</p><p>Protein arginine methyltransferase (<italic toggle="yes">PRMT</italic>) is a histone methyltransferase (HMT) that methylates glycine- and arginine-rich motifs (GAR motifs). <italic toggle="yes">PRMTs</italic> are classified into three groups according to their differences in catalytic activity: type I (<italic toggle="yes">PRMT1, 2, 3, 6</italic>, and <italic toggle="yes">8</italic>, <italic toggle="yes">CARM1</italic> [<italic toggle="yes">PRMT4</italic>]), type II (<italic toggle="yes">PRMT5</italic> and <italic toggle="yes">9</italic>), and type III (<italic toggle="yes">PRMT7</italic>). Next, we focused on discussing the relationship among <italic toggle="yes">PRMT2</italic>, <italic toggle="yes">PRMT8, PRMT7</italic>, and previous findings. The mRNA expression analysis of <italic toggle="yes">PRMT2</italic> showed a negative median range in patients with breast cancer, and the high-risk group of GC1 reflected disputable consequences in this study. Previous studies also indicated that the role of <italic toggle="yes">PRMT2</italic> in breast cancer progression remains controversial. A study suggested that spliced variants of <italic toggle="yes">PRMT2</italic> are capable of binding to ER&#945;, which further promotes EHMTR&#945;-mediated EMT-related genes E-cadherin and Snail [<xref rid="B35-ijms-24-05583" ref-type="bibr">35</xref>]. However, other studies indicated that the loss of PRMT2 may be essential for increasing the invasiveness of breast cancer [<xref rid="B36-ijms-24-05583" ref-type="bibr">36</xref>,<xref rid="B37-ijms-24-05583" ref-type="bibr">37</xref>]. Therefore, it is necessary to further study the function of <italic toggle="yes">PRMT2</italic> in breast cancer. PRMT8 is an enzyme whose exact mechanism of action in breast cancer is poorly understood. Previous study indicated that PRMT8 was associated with a poor prognosis via z-score analysis, whereas the Kaplan-Meier plot showed a protective trend for breast cancer [<xref rid="B38-ijms-24-05583" ref-type="bibr">38</xref>]. Another study observed that high <italic toggle="yes">PRMT8</italic> expression correlated with worse survival in gastric cancer; however, increased survival was observed in patients with breast and ovarian cancer. These contrasting results may be attributed to variant-specific expression of PRMT8, including the novel <italic toggle="yes">PRMT8</italic> variant 2 [<xref rid="B39-ijms-24-05583" ref-type="bibr">39</xref>]. This may explain why <italic toggle="yes">PRMT8</italic> in GC1 was negatively expressed in both the high- and low-risk subgroups. E-cadherin, an essential biomarker of EMT, is downregulated by <italic toggle="yes">PRMT7</italic> at its promoter, with elevated H4R3me3 and decreased H3K4me3, H3, and H4Ac. <italic toggle="yes">PRMT7</italic> interferes with E-cadherin expression through the PRMT7-YY1-HDAC3 complex, thus inducing cell migration and invasion in the MDA-MB-231 TNBC cell line [<xref rid="B40-ijms-24-05583" ref-type="bibr">40</xref>]. However, the results of our study showed higher expression of <italic toggle="yes">PRMT7</italic> in the low-risk subgroup of GC1, which may indicate an insidious pathway or variations in <italic toggle="yes">PRMT7</italic> enzyme activity.</p><p>To date, the <italic toggle="yes">PRDM</italic> families were found to contain 19 proteins that presented with a PR domain in the N-terminal region and variable numbers of zinc finger repeats [<xref rid="B24-ijms-24-05583" ref-type="bibr">24</xref>]. Hierarchical clustering analysis selected 6 PRDMs (<italic toggle="yes">PRDM7, 9, 12, 13, 14, 15</italic>) in GC1, and half of them showed negative expression (<italic toggle="yes">PRDM7, 9, 14</italic>), whereas the rest showed positive expression (<italic toggle="yes">PRDM12</italic>, <italic toggle="yes">13</italic>, <italic toggle="yes">15</italic>) in the high-risk group. However, studies of PRDM7 and carcinogenesis are limited. Sorrentino et al. observed that PRDM7 was overexpressed in hepatocarcinoma specimens through pan-cancer reanalysis of TCGA datasets. PRDM9 has been reported to interfere with homologous recombination by binding DNA using its zinc fingers, and H3K4/36me3 occurs in surrounding nucleosomes [<xref rid="B41-ijms-24-05583" ref-type="bibr">41</xref>]. It involves overlapping mechanisms of DSB during meiosis and mitosis [<xref rid="B42-ijms-24-05583" ref-type="bibr">42</xref>,<xref rid="B43-ijms-24-05583" ref-type="bibr">43</xref>]. Mutations in <italic toggle="yes">PRDM9</italic> have yet to be correlated with some solid tumors, such as head and neck squamous cell carcinoma and bladder cancer [<xref rid="B44-ijms-24-05583" ref-type="bibr">44</xref>,<xref rid="B45-ijms-24-05583" ref-type="bibr">45</xref>]. Previous studies suggested that <italic toggle="yes">PRDM12</italic> may act as a tumor suppressor in patients with CML [<xref rid="B46-ijms-24-05583" ref-type="bibr">46</xref>]. However, several studies indicated that <italic toggle="yes">PRDM12</italic> is upregulated in prostate and colon cancers compared to normal tissues [<xref rid="B47-ijms-24-05583" ref-type="bibr">47</xref>]. <italic toggle="yes">PRDM13</italic> acts as an anti-proliferation regulator by upregulating <italic toggle="yes">INCA1</italic>, a CDK inhibitor, and <italic toggle="yes">ADAMTS12</italic>, thereby inhibiting cell invasion. Overexpression of <italic toggle="yes">PRDM13</italic> in U87 glioma cells significantly inhibits cell migration and invasion by interacting with deleted liver cancer 1 (DLC1) and ARHGAP30 (Rho GTPase-activating protein 30) genes [<xref rid="B48-ijms-24-05583" ref-type="bibr">48</xref>]. However, pan-cancer reanalysis has shown high <italic toggle="yes">PRDM13</italic> overexpression in many cancers. These results are consistent with our study, in which <italic toggle="yes">PRDM13</italic> expression was higher in the high-risk subgroup of GC1. <italic toggle="yes">PRDM15</italic> could be a key regulator in diffuse large B-cell lymphoma (DLBCL), which sustained the activity of the PI3K/AKT/mTOR pathway and glycolysis [<xref rid="B49-ijms-24-05583" ref-type="bibr">49</xref>]. In addition, <italic toggle="yes">PRDM15</italic> could also stabilize the na&#239;ve pluripotency of embryonic development by modulating the transcription of upstream regulators of WNT and MAPK-ERK signaling [<xref rid="B50-ijms-24-05583" ref-type="bibr">50</xref>]. Previous studies found that there is elevated expression of <italic toggle="yes">PRDM14</italic> in breast cancer, whereas low or no expression was found in non-tumorous cells. Moreover, its amplification has been correlated with more aggressive cases of breast cancer, including high-grade and distant metastases. Knockdown of <italic toggle="yes">PRDM14</italic> suppressed cell growth by inducing apoptosis and increasing sensitivity to chemotherapy agents [<xref rid="B51-ijms-24-05583" ref-type="bibr">51</xref>,<xref rid="B52-ijms-24-05583" ref-type="bibr">52</xref>,<xref rid="B53-ijms-24-05583" ref-type="bibr">53</xref>]. However, <italic toggle="yes">PRDM14</italic> mRNA expression was negative for both high- and low-risk GC1 in our study. Evidence has shown that significant <italic toggle="yes">PRDM14</italic> methylation occurs in high-grade non-muscle invasive bladder, colon, and lung cancers. <italic toggle="yes">PRDM14</italic>&#8242;s role as a tumor suppressor&#8212;and whether its variant isoform exists&#8212;remains unknown [<xref rid="B54-ijms-24-05583" ref-type="bibr">54</xref>,<xref rid="B55-ijms-24-05583" ref-type="bibr">55</xref>,<xref rid="B56-ijms-24-05583" ref-type="bibr">56</xref>].</p><p>Based on the provided information, our study found that the expression of a combination of genes, including <italic toggle="yes">DNMT1, DNMT2, DNMT3A, DNMT3B, DNMT3L, HDAC1, HDAC2, HDAC3, PRDM7, PRDM9, PRDM12, PRDM13, PRDM14, PRDM15, PRMT1, PRMT2, PRMT5, PRMT6, PRMT7</italic>, and <italic toggle="yes">PRMT8</italic>, could be associated with an increased risk of poor PFS in patients with lymph node invasion. Additionally, the study suggested that the combination of chemotherapy and radiotherapy may be more effective in improving PFS compared to chemotherapy alone. We also tried to determine crosstalk between pathways with four gene families, including DNMT, HDAC, PRMT, and PRDM, which were illustrated using Ingenuity pathway analysis (IPA) systems (<xref rid="app1-ijms-24-05583" ref-type="app">Figure S9</xref>). The possible mechanisms underlying these findings are not clear from the information provided, but some of the genes identified in the study are known to be involved in epigenetic regulation and protein modification. It is possible that the combination of these genes could be involved in the regulation of key pathways involved in cancer progression, such as cell proliferation, apoptosis, and DNA repair. Further studies would be needed to confirm these findings and to investigate the underlying mechanisms in more detail.</p><p>The limitations of our study are the relatively small sample size and the lack of clinical practice. Nonetheless, the study gives us an indication that epigenetic modifications may play a crucial role in breast cancer tumorigenicity and could be a therapeutic target in the future.</p></sec><sec id="sec4-ijms-24-05583"><title>4. Material and Methods</title><sec id="sec4dot1-ijms-24-05583"><title>4.1. Data Source</title><p>All data were downloaded from the TCGA Pan-Cancer BRCA project via the cBioPortal platform [<xref rid="B57-ijms-24-05583" ref-type="bibr">57</xref>,<xref rid="B58-ijms-24-05583" ref-type="bibr">58</xref>]. This study included patients with non-metastatic breast cancer diagnosed as invasive ductal carcinoma by histological confirmation. Baseline characteristics included age at diagnosis, subtype, stage of tumor size, lymph node invasion status, pathological stage, radiotherapy, and chemotherapy. Progression-free survival (PFS) was considered as the primary endpoint of the study population. All patients were tracked from the date of initial diagnosis to the date of disease progression, metastasis, or the end of the study.</p></sec><sec id="sec4dot2-ijms-24-05583"><title>4.2. Messenger RNA (mRNA) Expression</title><p>The differential expression of candidate genes was estimated using raw digital gene expression counts, which were normalized using the variation of the reads/Kb/Million (RPKM). mRNA expression indicates the RPKM-normalized log2-transformed differential expression profiles (comparing the expression z-scores of tumor samples and adjacent normal samples in the study cohort) for the candidate genes. The mRNA expression of the candidate genes in all patients was visualized using a heatmap and the correlation between candidate genes were illustrated using a heatmap and tested using Pearson&#8217;s correlation test.</p></sec><sec id="sec4dot3-ijms-24-05583"><title>4.3. Hierarchical Clustering</title><p>The mRNA expression levels of candidate genes were normalized into a range of 0 to 1. The average silhouette width in <italic toggle="yes">k</italic> clusters was calculated to determine the optimal number of clusters for the candidate genes. Hierarchical clustering was conducted to generate dendrograms for candidate genes according to the gene similarity in mRNA expression. The greatest silhouette width was considered the optimal number of clusters to ensure the greatest dissimilarity between the identified <italic toggle="yes">n</italic> gene clusters. The cluster plot of candidate genes generated according to the assigned <italic toggle="yes">n</italic> gene clusters showed the similarity of the clustered genes in a two-dimensional distribution. Next, mRNA expression in the <italic toggle="yes">n</italic> gene cluster was used to dichotomize the study population into two risk estimation subgroups according to PFS status. The cutoff criteria for the two risk estimation subgroups were determined based on the distance metrics computed using a hierarchical algorithm based on the similarity of correspond mRNA expression. The computed distances were then used to establish cutoff values that separated the study population into two risk estimation subgroups, the subgroup with a higher proportion of disease progression was classified as the high-risk group, while the subgroup with a lower proportion was classified as the low-risk group.</p></sec><sec id="sec4dot4-ijms-24-05583"><title>4.4. Statistical Analysis</title><p>The baseline characteristics of all patients and the risk estimation subgroup determined by each gene cluster were summarized as frequency and percentage, and age at diagnosis was summarized by mean and standard deviation. The difference in baseline characteristic distribution between the risk estimation subgroups was estimated using an independent two-sampled t-test or chi-squared test. The mRNA expression of all candidate genes in all patients and the risk estimation subgroup were summarized using medians and ranges. The difference in mRNA expression between the risk-estimation subgroups was estimated using the Wilcoxon rank-sum test. The PFS between risk estimation subgroups in all patients, different lymph node invasion status, and treatment groups was estimated using the Kaplan&#8211;Meier method, and the survival difference between subgroups was tested using the log-rank test. All <italic toggle="yes">p</italic>-values were two-sided, and statistical significance was set at <italic toggle="yes">p</italic> &lt; 0.05. All analyses were performed using the R 4.0.5 software (R Core Team, Vienna, Austria, 2021).</p></sec></sec><sec sec-type="conclusions" id="sec5-ijms-24-05583"><title>5. Conclusions</title><p>In this study, we aimed to identify an optimal predictive biomarker for TNBC. First, we searched the TCGA database to select 486 patients, and 31 candidate genes were identified. The hierarchical clustering analysis represented two clusters according to the optimal number. GC1 was significantly associated with patients with breast cancer. Second, Kaplan&#8211;Meier analysis showed shorter PFS in the high-risk group of GC1 and lymph node invasion subgroups. The trend of improved PFS in the chemotherapy combined with radiotherapy group suggests that the high risk in GC1 genes may indicate better prognosis under treatment. Herein, we propose that the high-risk group genes in GC1 may be promising predictive biomarkers and predict clinical benefits from chemotherapy combined with radiotherapy.</p></sec></body><back><fn-group><fn><p><bold>Disclaimer/Publisher&#8217;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><app-group><app id="app1-ijms-24-05583"><title>Supplementary Materials</title><p>The following supporting information can be downloaded at: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/ijms24065583/s1">https://www.mdpi.com/article/10.3390/ijms24065583/s1</uri>.</p><supplementary-material id="ijms-24-05583-s001" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ijms-24-05583-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Methodology, S.-H.M. and M.-F.H.; Software, S.-H.M.; Validation, S.-H.M. and C.-W.L.; Investigation, C.-Y.K.; Resources, M.-F.H.; Data curation, C.-Y.K. and C.-W.L.; Writing&#8212;original draft, C.-Y.K.; Writing&#8212;review &amp; editing, C.-W.L. and M.-R.P.; Supervision, M.-F.H. and M.-R.P.; Project administration, M.-R.P.; Funding acquisition, M.-R.P. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Institutional Review Board Statement</title><p>Not applicable.</p></notes><notes><title>Informed Consent Statement</title><p>Not applicable.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>TCGA data portal is freely accessible and offering downloadable data sets, which can be accessed at cBioportal platform (<uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cbioportal.org/study/summary?id=brca_tcga_pan_can_atlas_2018">https://www.cbioportal.org/study/summary?id=brca_tcga_pan_can_atlas_2018</uri>). The BRCA data set, publicly accessible through the TCGA database, was the primary data source utilized in this study.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare that they have no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-ijms-24-05583"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wilkinson</surname><given-names>L.</given-names></name><name name-style="western"><surname>Gathani</surname><given-names>T.</given-names></name></person-group><article-title>Understanding breast cancer as a global health concern</article-title><source>Br. J. Radiol.</source><year>2022</year><volume>95</volume><fpage>20211033</fpage><pub-id pub-id-type="doi">10.1259/bjr.20211033</pub-id><pub-id pub-id-type="pmid">34905391</pub-id><pub-id pub-id-type="pmcid">PMC8822551</pub-id></element-citation></ref><ref id="B2-ijms-24-05583"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Waks</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Winer</surname><given-names>E.P.</given-names></name></person-group><article-title>Breast Cancer Treatment: A Review</article-title><source>JAMA</source><year>2019</year><volume>321</volume><fpage>288</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1001/jama.2018.19323</pub-id><pub-id pub-id-type="pmid">30667505</pub-id></element-citation></ref><ref id="B3-ijms-24-05583"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Francis</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Pagani</surname><given-names>O.</given-names></name><name name-style="western"><surname>Fleming</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Walley</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Colleoni</surname><given-names>M.</given-names></name><name name-style="western"><surname>L&#225;ng</surname><given-names>I.</given-names></name><name name-style="western"><surname>G&#243;mez</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Tondini</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ciruelos</surname><given-names>E.</given-names></name><name name-style="western"><surname>Burstein</surname><given-names>H.J.</given-names></name><etal/></person-group><article-title>Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>379</volume><fpage>122</fpage><lpage>137</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1803164</pub-id><pub-id pub-id-type="pmid">29863451</pub-id><pub-id pub-id-type="pmcid">PMC6193457</pub-id></element-citation></ref><ref id="B4-ijms-24-05583"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cameron</surname><given-names>D.</given-names></name><name name-style="western"><surname>Piccart-Gebhart</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Gelber</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Procter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Goldhirsch</surname><given-names>A.</given-names></name><name name-style="western"><surname>de Azambuja</surname><given-names>E.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>G.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Untch</surname><given-names>M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>I.</given-names></name><name name-style="western"><surname>Gianni</surname><given-names>L.</given-names></name><etal/></person-group><article-title>11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: Final analysis of the HERceptin Adjuvant (HERA) trial</article-title><source>Lancet</source><year>2017</year><volume>389</volume><fpage>1195</fpage><lpage>1205</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(16)32616-2</pub-id><pub-id pub-id-type="pmid">28215665</pub-id><pub-id pub-id-type="pmcid">PMC5465633</pub-id></element-citation></ref><ref id="B5-ijms-24-05583"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trail</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Dubowchik</surname><given-names>G.M.</given-names></name><name name-style="western"><surname>Lowinger</surname><given-names>T.B.</given-names></name></person-group><article-title>Antibody drug conjugates for treatment of breast cancer: Novel targets and diverse approaches in ADC design</article-title><source>Pharmacol. Ther.</source><year>2018</year><volume>181</volume><fpage>126</fpage><lpage>142</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2017.07.013</pub-id><pub-id pub-id-type="pmid">28757155</pub-id></element-citation></ref><ref id="B6-ijms-24-05583"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blum</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Flynn</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Yothers</surname><given-names>G.</given-names></name><name name-style="western"><surname>Asmar</surname><given-names>L.</given-names></name><name name-style="western"><surname>Geyer</surname><given-names>C.E.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Jacobs</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Robert</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Hopkins</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>O'Shaughnessy</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Dang</surname><given-names>C.T.</given-names></name><etal/></person-group><article-title>Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)</article-title><source>J. Clin. Oncol.</source><year>2017</year><volume>35</volume><fpage>2647</fpage><lpage>2655</lpage><pub-id pub-id-type="doi">10.1200/JCO.2016.71.4147</pub-id><pub-id pub-id-type="pmid">28398846</pub-id><pub-id pub-id-type="pmcid">PMC5549453</pub-id></element-citation></ref><ref id="B7-ijms-24-05583"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Masood</surname><given-names>S.</given-names></name></person-group><article-title>Neoadjuvant chemotherapy in breast cancers</article-title><source>Womens Health</source><year>2016</year><volume>12</volume><fpage>480</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1177/1745505716677139</pub-id><pub-id pub-id-type="pmcid">PMC5373271</pub-id><pub-id pub-id-type="pmid">27885165</pub-id></element-citation></ref><ref id="B8-ijms-24-05583"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chavez-MacGregor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mittendorf</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Lichtensztajn</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Hunt</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Giordano</surname><given-names>S.H.</given-names></name></person-group><article-title>Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System</article-title><source>Oncologist</source><year>2017</year><volume>22</volume><fpage>1292</fpage><lpage>1300</lpage><pub-id pub-id-type="doi">10.1634/theoncologist.2017-0116</pub-id><pub-id pub-id-type="pmid">28592619</pub-id><pub-id pub-id-type="pmcid">PMC5679819</pub-id></element-citation></ref><ref id="B9-ijms-24-05583"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davies</surname><given-names>C.</given-names></name><name name-style="western"><surname>Godwin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>R.</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cutter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Darby</surname><given-names>S.</given-names></name><name name-style="western"><surname>McGale</surname><given-names>P.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H.C.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.C.</given-names></name><etal/></person-group><article-title>Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials</article-title><source>Lancet</source><year>2011</year><volume>378</volume><fpage>771</fpage><lpage>784</lpage><pub-id pub-id-type="doi">10.1016/s0140-6736(11)60993-8</pub-id><pub-id pub-id-type="pmid">21802721</pub-id><pub-id pub-id-type="pmcid">PMC3163848</pub-id></element-citation></ref><ref id="B10-ijms-24-05583"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swain</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Baselga</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Ro</surname><given-names>J.</given-names></name><name name-style="western"><surname>Semiglazov</surname><given-names>V.</given-names></name><name name-style="western"><surname>Campone</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ciruelos</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ferrero</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Schneeweiss</surname><given-names>A.</given-names></name><name name-style="western"><surname>Heeson</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer</article-title><source>N. Engl. J. Med.</source><year>2015</year><volume>372</volume><fpage>724</fpage><lpage>734</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1413513</pub-id><pub-id pub-id-type="pmid">25693012</pub-id><pub-id pub-id-type="pmcid">PMC5584549</pub-id></element-citation></ref><ref id="B11-ijms-24-05583"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sparano</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Makower</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Pritchard</surname><given-names>K.I.</given-names></name><name name-style="western"><surname>Albain</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>D.F.</given-names></name><name name-style="western"><surname>Geyer</surname><given-names>C.E.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Dees</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Goetz</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>J.A.</given-names><suffix>Jr.</suffix></name><etal/></person-group><article-title>Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer</article-title><source>N. Engl. J. Med.</source><year>2018</year><volume>379</volume><fpage>111</fpage><lpage>121</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1804710</pub-id><pub-id pub-id-type="pmid">29860917</pub-id><pub-id pub-id-type="pmcid">PMC6172658</pub-id></element-citation></ref><ref id="B12-ijms-24-05583"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cardoso</surname><given-names>F.</given-names></name><name name-style="western"><surname>van't Veer</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Bogaerts</surname><given-names>J.</given-names></name><name name-style="western"><surname>Slaets</surname><given-names>L.</given-names></name><name name-style="western"><surname>Viale</surname><given-names>G.</given-names></name><name name-style="western"><surname>Delaloge</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pierga</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Brain</surname><given-names>E.</given-names></name><name name-style="western"><surname>Causeret</surname><given-names>S.</given-names></name><name name-style="western"><surname>DeLorenzi</surname><given-names>M.</given-names></name><etal/></person-group><article-title>70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer</article-title><source>N. Engl. J. Med.</source><year>2016</year><volume>375</volume><fpage>717</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1602253</pub-id><pub-id pub-id-type="pmid">27557300</pub-id></element-citation></ref><ref id="B13-ijms-24-05583"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>L&#230;nkholm</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Eriksen</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Rasmussen</surname><given-names>B.B.</given-names></name><name name-style="western"><surname>Knoop</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Buckingham</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ferree</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schaper</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nielsen</surname><given-names>T.O.</given-names></name><name name-style="western"><surname>Haffner</surname><given-names>T.</given-names></name><etal/></person-group><article-title>PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor-Positive Early Breast Cancer</article-title><source>J. Clin. Oncol.</source><year>2018</year><volume>36</volume><fpage>735</fpage><lpage>740</lpage><pub-id pub-id-type="doi">10.1200/JCO.2017.74.6586</pub-id><pub-id pub-id-type="pmid">29369732</pub-id></element-citation></ref><ref id="B14-ijms-24-05583"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sestak</surname><given-names>I.</given-names></name><name name-style="western"><surname>Mart&#237;n</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dubsky</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kronenwett</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rojo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Cuzick</surname><given-names>J.</given-names></name><name name-style="western"><surname>Filipits</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ruiz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gradishar</surname><given-names>W.</given-names></name><name name-style="western"><surname>Soliman</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone</article-title><source>Breast Cancer Res. Treat.</source><year>2019</year><volume>176</volume><fpage>377</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1007/s10549-019-05226-8</pub-id><pub-id pub-id-type="pmid">31041683</pub-id><pub-id pub-id-type="pmcid">PMC6555778</pub-id></element-citation></ref><ref id="B15-ijms-24-05583"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Noordhoek</surname><given-names>I.</given-names></name><name name-style="western"><surname>Treuner</surname><given-names>K.</given-names></name><name name-style="western"><surname>Putter</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meershoek-Klein Kranenbarg</surname><given-names>E.</given-names></name><name name-style="western"><surname>Duijm-de Carpentier</surname><given-names>M.</given-names></name><name name-style="western"><surname>van de Velde</surname><given-names>C.J.H.</given-names></name><name name-style="western"><surname>Schnabel</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Liefers</surname><given-names>G.J.</given-names></name></person-group><article-title>Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR(+) Early-stage Breast Cancer for 10 Years of Endocrine Therapy</article-title><source>Clin. Cancer Res.</source><year>2021</year><volume>27</volume><fpage>311</fpage><lpage>319</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-20-2737</pub-id><pub-id pub-id-type="pmid">33109739</pub-id></element-citation></ref><ref id="B16-ijms-24-05583"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vieira</surname><given-names>A.F.</given-names></name><name name-style="western"><surname>Schmitt</surname><given-names>F.</given-names></name></person-group><article-title>An Update on Breast Cancer Multigene Prognostic Tests-Emergent Clinical Biomarkers</article-title><source>Front. Med.</source><year>2018</year><volume>5</volume><fpage>248</fpage><pub-id pub-id-type="doi">10.3389/fmed.2018.00248</pub-id><pub-id pub-id-type="pmcid">PMC6131478</pub-id><pub-id pub-id-type="pmid">30234119</pub-id></element-citation></ref><ref id="B17-ijms-24-05583"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bartlett</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Bayani</surname><given-names>J.</given-names></name><name name-style="western"><surname>Marshall</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>C.</given-names></name><name name-style="western"><surname>Sobol</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Poole</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>D.A.</given-names></name><etal/></person-group><article-title>Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others</article-title><source>J. Natl. Cancer Inst.</source><year>2016</year><volume>108</volume><fpage>djw050</fpage><pub-id pub-id-type="doi">10.1093/jnci/djw050</pub-id><pub-id pub-id-type="pmid">27130929</pub-id><pub-id pub-id-type="pmcid">PMC5939629</pub-id></element-citation></ref><ref id="B18-ijms-24-05583"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bianchini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Qi</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Alvarez</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Iwamoto</surname><given-names>T.</given-names></name><name name-style="western"><surname>Coutant</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ibrahim</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Valero</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cristofanilli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Green</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Radvanyi</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers</article-title><source>J. Clin. Oncol.</source><year>2010</year><volume>28</volume><fpage>4316</fpage><lpage>4323</lpage><pub-id pub-id-type="doi">10.1200/JCO.2009.27.2419</pub-id><pub-id pub-id-type="pmid">20805453</pub-id></element-citation></ref><ref id="B19-ijms-24-05583"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Han</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.</given-names></name></person-group><article-title>Targeting epigenetic regulators for cancer therapy: Mechanisms and advances in clinical trials</article-title><source>Signal Transduct. Target. Ther.</source><year>2019</year><volume>4</volume><fpage>62</fpage><pub-id pub-id-type="doi">10.1038/s41392-019-0095-0</pub-id><pub-id pub-id-type="pmid">31871779</pub-id><pub-id pub-id-type="pmcid">PMC6915746</pub-id></element-citation></ref><ref id="B20-ijms-24-05583"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dworkin</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Toland</surname><given-names>A.E.</given-names></name></person-group><article-title>Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment</article-title><source>Semin. Cancer Biol.</source><year>2009</year><volume>19</volume><fpage>165</fpage><lpage>171</lpage><pub-id pub-id-type="doi">10.1016/j.semcancer.2009.02.007</pub-id><pub-id pub-id-type="pmid">19429480</pub-id><pub-id pub-id-type="pmcid">PMC2734184</pub-id></element-citation></ref><ref id="B21-ijms-24-05583"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stefansson</surname><given-names>O.A.</given-names></name><name name-style="western"><surname>Esteller</surname><given-names>M.</given-names></name></person-group><article-title>Epigenetic modifications in breast cancer and their role in personalized medicine</article-title><source>Am. J. Pathol.</source><year>2013</year><volume>183</volume><fpage>1052</fpage><lpage>1063</lpage><pub-id pub-id-type="doi">10.1016/j.ajpath.2013.04.033</pub-id><pub-id pub-id-type="pmid">23899662</pub-id></element-citation></ref><ref id="B22-ijms-24-05583"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Martinez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Nakata</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>H.L.</given-names></name><name name-style="western"><surname>Morey</surname><given-names>L.</given-names></name></person-group><article-title>Epigenetic mechanisms in breast cancer therapy and resistance</article-title><source>Nat. Commun.</source><year>2021</year><volume>12</volume><fpage>1786</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-22024-3</pub-id><pub-id pub-id-type="pmid">33741974</pub-id><pub-id pub-id-type="pmcid">PMC7979820</pub-id></element-citation></ref><ref id="B23-ijms-24-05583"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Delcuve</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>D.H.</given-names></name><name name-style="western"><surname>Davie</surname><given-names>J.R.</given-names></name></person-group><article-title>Roles of histone deacetylases in epigenetic regulation: Emerging paradigms from studies with inhibitors</article-title><source>Clin. Epigenetics</source><year>2012</year><volume>4</volume><fpage>5</fpage><pub-id pub-id-type="doi">10.1186/1868-7083-4-5</pub-id><pub-id pub-id-type="pmid">22414492</pub-id><pub-id pub-id-type="pmcid">PMC3320549</pub-id></element-citation></ref><ref id="B24-ijms-24-05583"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Casamassimi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rienzo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Di Zazzo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sorrentino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fiore</surname><given-names>D.</given-names></name><name name-style="western"><surname>Proto</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Moncharmont</surname><given-names>B.</given-names></name><name name-style="western"><surname>Gazzerro</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bifulco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Abbondanza</surname><given-names>C.</given-names></name></person-group><article-title>Multifaceted Role of PRDM Proteins in Human Cancer</article-title><source>Int. J. Mol. Sci.</source><year>2020</year><volume>21</volume><elocation-id>2648</elocation-id><pub-id pub-id-type="doi">10.3390/ijms21072648</pub-id><pub-id pub-id-type="pmid">32290321</pub-id><pub-id pub-id-type="pmcid">PMC7177584</pub-id></element-citation></ref><ref id="B25-ijms-24-05583"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Seto</surname><given-names>E.</given-names></name></person-group><article-title>HDACs and HDAC Inhibitors in Cancer Development and Therapy</article-title><source>Cold Spring Harb. Perspect. Med.</source><year>2016</year><volume>6</volume><fpage>a026831</fpage><pub-id pub-id-type="doi">10.1101/cshperspect.a026831</pub-id><pub-id pub-id-type="pmid">27599530</pub-id><pub-id pub-id-type="pmcid">PMC5046688</pub-id></element-citation></ref><ref id="B26-ijms-24-05583"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malone</surname><given-names>E.R.</given-names></name><name name-style="western"><surname>Oliva</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sabatini</surname><given-names>P.J.B.</given-names></name><name name-style="western"><surname>Stockley</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Siu</surname><given-names>L.L.</given-names></name></person-group><article-title>Molecular profiling for precision cancer therapies</article-title><source>Genome Med.</source><year>2020</year><volume>12</volume><fpage>8</fpage><pub-id pub-id-type="doi">10.1186/s13073-019-0703-1</pub-id><pub-id pub-id-type="pmid">31937368</pub-id><pub-id pub-id-type="pmcid">PMC6961404</pub-id></element-citation></ref><ref id="B27-ijms-24-05583"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ghoncheh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pournamdar</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Salehiniya</surname><given-names>H.</given-names></name></person-group><article-title>Incidence and Mortality and Epidemiology of Breast Cancer in the World</article-title><source>Asian Pac. J. Cancer Prev.</source><year>2016</year><volume>17</volume><fpage>43</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.7314/APJCP.2016.17.S3.43</pub-id><pub-id pub-id-type="pmid">27165206</pub-id></element-citation></ref><ref id="B28-ijms-24-05583"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yin</surname><given-names>L.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Bian</surname><given-names>X.W.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>S.C.</given-names></name></person-group><article-title>Triple-negative breast cancer molecular subtyping and treatment progress</article-title><source>Breast Cancer Res.</source><year>2020</year><volume>22</volume><fpage>61</fpage><pub-id pub-id-type="doi">10.1186/s13058-020-01296-5</pub-id><pub-id pub-id-type="pmid">32517735</pub-id><pub-id pub-id-type="pmcid">PMC7285581</pub-id></element-citation></ref><ref id="B29-ijms-24-05583"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cyprian</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Akhtar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gatalica</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Vranic</surname><given-names>S.</given-names></name></person-group><article-title>Targeted immunotherapy with a checkpoint inhibitor in combination with chemotherapy: A new clinical paradigm in the treatment of triple-negative breast cancer</article-title><source>Bosn. J. Basic Med. Sci.</source><year>2019</year><volume>19</volume><fpage>227</fpage><lpage>233</lpage><pub-id pub-id-type="doi">10.17305/bjbms.2019.4204</pub-id><pub-id pub-id-type="pmid">30915922</pub-id><pub-id pub-id-type="pmcid">PMC6716092</pub-id></element-citation></ref><ref id="B30-ijms-24-05583"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmer</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Gillard</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lipkowitz</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.M.</given-names></name></person-group><article-title>Update on PARP Inhibitors in Breast Cancer</article-title><source>Curr. Treat. Options Oncol.</source><year>2018</year><volume>19</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1007/s11864-018-0540-2</pub-id><pub-id pub-id-type="pmid">29644491</pub-id><pub-id pub-id-type="pmcid">PMC7430202</pub-id></element-citation></ref><ref id="B31-ijms-24-05583"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nedeljkovi&#263;</surname><given-names>M.</given-names></name><name name-style="western"><surname>Damjanovi&#263;</surname><given-names>A.</given-names></name></person-group><article-title>Mechanisms of Chemotherapy Resistance in Triple-Negative Breast Cancer-How We Can Rise to the Challenge</article-title><source>Cells</source><year>2019</year><volume>8</volume><elocation-id>957</elocation-id><pub-id pub-id-type="doi">10.3390/cells8090957</pub-id><pub-id pub-id-type="pmid">31443516</pub-id><pub-id pub-id-type="pmcid">PMC6770896</pub-id></element-citation></ref><ref id="B32-ijms-24-05583"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mirza</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>G.</given-names></name><name name-style="western"><surname>Parshad</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Pandya</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ralhan</surname><given-names>R.</given-names></name></person-group><article-title>Expression of DNA methyltransferases in breast cancer patients and to analyze the effect of natural compounds on DNA methyltransferases and associated proteins</article-title><source>J. Breast Cancer</source><year>2013</year><volume>16</volume><fpage>23</fpage><lpage>31</lpage><pub-id pub-id-type="doi">10.4048/jbc.2013.16.1.23</pub-id><pub-id pub-id-type="pmid">23593078</pub-id><pub-id pub-id-type="pmcid">PMC3625766</pub-id></element-citation></ref><ref id="B33-ijms-24-05583"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feng</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>R.Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Seto</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liao</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>Y.</given-names></name></person-group><article-title>Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer</article-title><source>Int. J. Cancer</source><year>2007</year><volume>120</volume><fpage>1664</fpage><lpage>1668</lpage><pub-id pub-id-type="doi">10.1002/ijc.22474</pub-id><pub-id pub-id-type="pmid">17230502</pub-id></element-citation></ref><ref id="B34-ijms-24-05583"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>G.K.</given-names></name><name name-style="western"><surname>Devries</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Benz</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Waldman</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>E.S.</given-names></name></person-group><article-title>Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression</article-title><source>Clin. Cancer Res.</source><year>2009</year><volume>15</volume><fpage>3163</fpage><lpage>3171</lpage><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-2319</pub-id><pub-id pub-id-type="pmid">19383825</pub-id><pub-id pub-id-type="pmcid">PMC3746548</pub-id></element-citation></ref><ref id="B35-ijms-24-05583"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>R.X.</given-names></name><name name-style="western"><surname>Zu</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Hong</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>X.H.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>Identification and characterization of novel spliced variants of PRMT2 in breast carcinoma</article-title><source>FEBS J.</source><year>2012</year><volume>279</volume><fpage>316</fpage><lpage>335</lpage><pub-id pub-id-type="doi">10.1111/j.1742-4658.2011.08426.x</pub-id><pub-id pub-id-type="pmid">22093364</pub-id></element-citation></ref><ref id="B36-ijms-24-05583"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>R.X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.B.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>Nuclear loss of protein arginine N-methyltransferase 2 in breast carcinoma is associated with tumor grade and overexpression of cyclin D1 protein</article-title><source>Oncogene</source><year>2014</year><volume>33</volume><fpage>5546</fpage><lpage>5558</lpage><pub-id pub-id-type="doi">10.1038/onc.2013.500</pub-id><pub-id pub-id-type="pmid">24292672</pub-id></element-citation></ref><ref id="B37-ijms-24-05583"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Y.Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Q.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>R.X.</given-names></name><name name-style="western"><surname>Zu</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>G.B.</given-names></name></person-group><article-title>PRMT2&#946;, a C-terminal splice variant of PRMT2, inhibits the growth of breast cancer cells</article-title><source>Oncol. Rep.</source><year>2017</year><volume>38</volume><fpage>1303</fpage><lpage>1311</lpage><pub-id pub-id-type="doi">10.3892/or.2017.5786</pub-id><pub-id pub-id-type="pmid">28677794</pub-id></element-citation></ref><ref id="B38-ijms-24-05583"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oh</surname><given-names>T.G.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Muscat</surname><given-names>G.E.</given-names></name></person-group><article-title>Therapeutic Implications of Epigenetic Signaling in Breast Cancer</article-title><source>Endocrinology</source><year>2017</year><volume>158</volume><fpage>431</fpage><lpage>447</lpage><pub-id pub-id-type="doi">10.1210/en.2016-1716</pub-id><pub-id pub-id-type="pmid">27983866</pub-id></element-citation></ref><ref id="B39-ijms-24-05583"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hernandez</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Dolivo</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Dominko</surname><given-names>T.</given-names></name></person-group><article-title>PRMT8 demonstrates variant-specific expression in cancer cells and correlates with patient survival in breast, ovarian and gastric cancer</article-title><source>Oncol. Lett.</source><year>2017</year><volume>13</volume><fpage>1983</fpage><lpage>1989</lpage><pub-id pub-id-type="doi">10.3892/ol.2017.5671</pub-id><pub-id pub-id-type="pmid">28454353</pub-id><pub-id pub-id-type="pmcid">PMC5403539</pub-id></element-citation></ref><ref id="B40-ijms-24-05583"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yao</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Du</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>P.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>G.</given-names></name><etal/></person-group><article-title>PRMT7 induces epithelial-to-mesenchymal transition and promotes metastasis in breast cancer</article-title><source>Cancer Res.</source><year>2014</year><volume>74</volume><fpage>5656</fpage><lpage>5667</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-0800</pub-id><pub-id pub-id-type="pmid">25136067</pub-id></element-citation></ref><ref id="B41-ijms-24-05583"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eram</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Bustos</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Lima-Fernandes</surname><given-names>E.</given-names></name><name name-style="western"><surname>Siarheyeva</surname><given-names>A.</given-names></name><name name-style="western"><surname>Senisterra</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hajian</surname><given-names>T.</given-names></name><name name-style="western"><surname>Chau</surname><given-names>I.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dombrovski</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Trimethylation of histone H3 lysine 36 by human methyltransferase PRDM9 protein</article-title><source>J. Biol. Chem.</source><year>2014</year><volume>289</volume><fpage>12177</fpage><lpage>12188</lpage><pub-id pub-id-type="doi">10.1074/jbc.M113.523183</pub-id><pub-id pub-id-type="pmid">24634223</pub-id><pub-id pub-id-type="pmcid">PMC4002121</pub-id></element-citation></ref><ref id="B42-ijms-24-05583"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alves</surname><given-names>I.</given-names></name><name name-style="western"><surname>Houle</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Hussin</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Awadalla</surname><given-names>P.</given-names></name></person-group><article-title>The impact of recombination on human mutation load and disease</article-title><source>Philos. Trans. R. Soc. Lond. B Biol. Sci.</source><year>2017</year><volume>372</volume><pub-id pub-id-type="doi">10.1098/rstb.2016.0465</pub-id><pub-id pub-id-type="pmid">29109227</pub-id><pub-id pub-id-type="pmcid">PMC5698626</pub-id></element-citation></ref><ref id="B43-ijms-24-05583"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paigen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Petkov</surname><given-names>P.M.</given-names></name></person-group><article-title>PRDM9 and Its Role in Genetic Recombination</article-title><source>Trends Genet.</source><year>2018</year><volume>34</volume><fpage>291</fpage><lpage>300</lpage><pub-id pub-id-type="doi">10.1016/j.tig.2017.12.017</pub-id><pub-id pub-id-type="pmid">29366606</pub-id><pub-id pub-id-type="pmcid">PMC5878713</pub-id></element-citation></ref><ref id="B44-ijms-24-05583"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>B.</given-names></name><name name-style="western"><surname>Yan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xia</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ye</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name></person-group><article-title>Analysis of the role of mutations in the KMT2D histone lysine methyltransferase in bladder cancer</article-title><source>FEBS Open Bio.</source><year>2019</year><volume>9</volume><fpage>693</fpage><lpage>706</lpage><pub-id pub-id-type="doi">10.1002/2211-5463.12600</pub-id><pub-id pub-id-type="pmid">30984543</pub-id><pub-id pub-id-type="pmcid">PMC6443872</pub-id></element-citation></ref><ref id="B45-ijms-24-05583"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zou</surname><given-names>A.E.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Saad</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Rahimy</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ku</surname><given-names>J.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>S.Z.</given-names></name><name name-style="western"><surname>Honda</surname><given-names>T.K.</given-names></name><name name-style="western"><surname>Wang-Rodriguez</surname><given-names>J.</given-names></name><name name-style="western"><surname>Xuan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Korrapati</surname><given-names>A.</given-names></name><etal/></person-group><article-title>The non-coding landscape of head and neck squamous cell carcinoma</article-title><source>Oncotarget</source><year>2016</year><volume>7</volume><fpage>51211</fpage><lpage>51222</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.9979</pub-id><pub-id pub-id-type="pmid">27323410</pub-id><pub-id pub-id-type="pmcid">PMC5239470</pub-id></element-citation></ref><ref id="B46-ijms-24-05583"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reid</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Nacheva</surname><given-names>E.P.</given-names></name></person-group><article-title>A potential role for PRDM12 in the pathogenesis of chronic myeloid leukaemia with derivative chromosome 9 deletion</article-title><source>Leukemia</source><year>2004</year><volume>18</volume><fpage>178</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1038/sj.leu.2403162</pub-id><pub-id pub-id-type="pmid">14523459</pub-id></element-citation></ref><ref id="B47-ijms-24-05583"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorrentino</surname><given-names>A.</given-names></name><name name-style="western"><surname>Federico</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rienzo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gazzerro</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bifulco</surname><given-names>M.</given-names></name><name name-style="western"><surname>Ciccodicola</surname><given-names>A.</given-names></name><name name-style="western"><surname>Casamassimi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Abbondanza</surname><given-names>C.</given-names></name></person-group><article-title>PR/SET Domain Family and Cancer: Novel Insights from the Cancer Genome Atlas</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>3250</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19103250</pub-id><pub-id pub-id-type="pmid">30347759</pub-id><pub-id pub-id-type="pmcid">PMC6214140</pub-id></element-citation></ref><ref id="B48-ijms-24-05583"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>H.</given-names></name><name name-style="western"><surname>He</surname><given-names>T.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Q.</given-names></name></person-group><article-title>Overexpression of PRDM13 inhibits glioma cells via Rho and GTP enzyme activation protein</article-title><source>Int. J. Mol. Med.</source><year>2018</year><volume>42</volume><fpage>966</fpage><lpage>974</lpage><pub-id pub-id-type="doi">10.3892/ijmm.2018.3679</pub-id><pub-id pub-id-type="pmid">29767251</pub-id><pub-id pub-id-type="pmcid">PMC6034930</pub-id></element-citation></ref><ref id="B49-ijms-24-05583"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mzoughi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fong</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Papadopoli</surname><given-names>D.</given-names></name><name name-style="western"><surname>Koh</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Hulea</surname><given-names>L.</given-names></name><name name-style="western"><surname>Pigini</surname><given-names>P.</given-names></name><name name-style="western"><surname>Di Tullio</surname><given-names>F.</given-names></name><name name-style="western"><surname>Andreacchio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hoppe</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Wollmann</surname><given-names>H.</given-names></name><etal/></person-group><article-title>PRDM15 is a key regulator of metabolism critical to sustain B-cell lymphomagenesis</article-title><source>Nat. Commun.</source><year>2020</year><volume>11</volume><fpage>3520</fpage><pub-id pub-id-type="doi">10.1038/s41467-020-17064-0</pub-id><pub-id pub-id-type="pmid">32665551</pub-id><pub-id pub-id-type="pmcid">PMC7360777</pub-id></element-citation></ref><ref id="B50-ijms-24-05583"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mzoughi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hequet</surname><given-names>D.</given-names></name><name name-style="western"><surname>Teo</surname><given-names>S.X.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Xing</surname><given-names>Q.R.</given-names></name><name name-style="western"><surname>Bezzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Seah</surname><given-names>M.K.Y.</given-names></name><name name-style="western"><surname>Ong</surname><given-names>S.L.M.</given-names></name><name name-style="western"><surname>Shin</surname><given-names>E.M.</given-names></name><etal/></person-group><article-title>PRDM15 safeguards naive pluripotency by transcriptionally regulating WNT and MAPK-ERK signaling</article-title><source>Nat. Genet.</source><year>2017</year><volume>49</volume><fpage>1354</fpage><lpage>1363</lpage><pub-id pub-id-type="doi">10.1038/ng.3922</pub-id><pub-id pub-id-type="pmid">28740264</pub-id></element-citation></ref><ref id="B51-ijms-24-05583"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moelans</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>de Weger</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Monsuur</surname><given-names>H.N.</given-names></name><name name-style="western"><surname>Vijzelaar</surname><given-names>R.</given-names></name><name name-style="western"><surname>van Diest</surname><given-names>P.J.</given-names></name></person-group><article-title>Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes</article-title><source>Mod. Pathol.</source><year>2010</year><volume>23</volume><fpage>1029</fpage><lpage>1039</lpage><pub-id pub-id-type="doi">10.1038/modpathol.2010.84</pub-id><pub-id pub-id-type="pmid">20473280</pub-id></element-citation></ref><ref id="B52-ijms-24-05583"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moelans</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>van der Groep</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hoefnagel</surname><given-names>L.D.C.</given-names></name><name name-style="western"><surname>van de Vijver</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Wesseling</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wesseling</surname><given-names>J.</given-names></name><name name-style="western"><surname>van der Wall</surname><given-names>E.</given-names></name><name name-style="western"><surname>van Diest</surname><given-names>P.J.</given-names></name></person-group><article-title>Genomic evolution from primary breast carcinoma to distant metastasis: Few copy number changes of breast cancer related genes</article-title><source>Cancer Lett.</source><year>2014</year><volume>344</volume><fpage>138</fpage><lpage>146</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2013.10.025</pub-id><pub-id pub-id-type="pmid">24184827</pub-id></element-citation></ref><ref id="B53-ijms-24-05583"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nishikawa</surname><given-names>N.</given-names></name><name name-style="western"><surname>Toyota</surname><given-names>M.</given-names></name><name name-style="western"><surname>Suzuki</surname><given-names>H.</given-names></name><name name-style="western"><surname>Honma</surname><given-names>T.</given-names></name><name name-style="western"><surname>Fujikane</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ohmura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Nishidate</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ohe-Toyota</surname><given-names>M.</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sonoda</surname><given-names>T.</given-names></name><etal/></person-group><article-title>Gene amplification and overexpression of PRDM14 in breast cancers</article-title><source>Cancer Res.</source><year>2007</year><volume>67</volume><fpage>9649</fpage><lpage>9657</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-06-4111</pub-id><pub-id pub-id-type="pmid">17942894</pub-id></element-citation></ref><ref id="B54-ijms-24-05583"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ashktorab</surname><given-names>H.</given-names></name><name name-style="western"><surname>Shakoori</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zarnogi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Varma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shokrani</surname><given-names>B.</given-names></name><name name-style="western"><surname>Laiyemo</surname><given-names>A.O.</given-names></name><name name-style="western"><surname>Washington</surname><given-names>K.</given-names></name><name name-style="western"><surname>Brim</surname><given-names>H.</given-names></name></person-group><article-title>Reduced Representation Bisulfite Sequencing Determination of Distinctive DNA Hypermethylated Genes in the Progression to Colon Cancer in African Americans</article-title><source>Gastroenterol. Res. Pract.</source><year>2016</year><volume>2016</volume><fpage>2102674</fpage><pub-id pub-id-type="doi">10.1155/2016/2102674</pub-id><pub-id pub-id-type="pmid">27688749</pub-id><pub-id pub-id-type="pmcid">PMC5023837</pub-id></element-citation></ref><ref id="B55-ijms-24-05583"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kitchen</surname><given-names>M.O.</given-names></name><name name-style="western"><surname>Bryan</surname><given-names>R.T.</given-names></name><name name-style="western"><surname>Emes</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Glossop</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Luscombe</surname><given-names>C.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>K.K.</given-names></name><name name-style="western"><surname>Zeegers</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>James</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Devall</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Mein</surname><given-names>C.A.</given-names></name><etal/></person-group><article-title>Quantitative genome-wide methylation analysis of high-grade non-muscle invasive bladder cancer</article-title><source>Epigenetics</source><year>2016</year><volume>11</volume><fpage>237</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1080/15592294.2016.1154246</pub-id><pub-id pub-id-type="pmid">26929985</pub-id><pub-id pub-id-type="pmcid">PMC4854556</pub-id></element-citation></ref><ref id="B56-ijms-24-05583"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hubers</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Brinkman</surname><given-names>P.</given-names></name><name name-style="western"><surname>Boksem</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Rhodius</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Witte</surname><given-names>B.I.</given-names></name><name name-style="western"><surname>Zwinderman</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Heideman</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Duin</surname><given-names>S.</given-names></name><name name-style="western"><surname>Koning</surname><given-names>R.</given-names></name><name name-style="western"><surname>Steenbergen</surname><given-names>R.D.</given-names></name><etal/></person-group><article-title>Combined sputum hypermethylation and eNose analysis for lung cancer diagnosis</article-title><source>J. Clin. Pathol.</source><year>2014</year><volume>67</volume><fpage>707</fpage><lpage>711</lpage><pub-id pub-id-type="doi">10.1136/jclinpath-2014-202414</pub-id><pub-id pub-id-type="pmid">24915850</pub-id></element-citation></ref><ref id="B57-ijms-24-05583"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lichtenberg</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hoadley</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Poisson</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Lazar</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Cherniack</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Kovatich</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Benz</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Levine</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>A.V.</given-names></name><etal/></person-group><article-title>An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics</article-title><source>Cell</source><year>2018</year><volume>173</volume><fpage>400</fpage><lpage>416.e411</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.02.052</pub-id><pub-id pub-id-type="pmid">29625055</pub-id><pub-id pub-id-type="pmcid">PMC6066282</pub-id></element-citation></ref><ref id="B58-ijms-24-05583"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hoadley</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Yau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hinoue</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wolf</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Lazar</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Drill</surname><given-names>E.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Cherniack</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Thorsson</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer</article-title><source>Cell</source><year>2018</year><volume>173</volume><fpage>291</fpage><lpage>304.e296</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.03.022</pub-id><pub-id pub-id-type="pmid">29625048</pub-id><pub-id pub-id-type="pmcid">PMC5957518</pub-id></element-citation></ref></ref-list></back><floats-group><fig position="float" id="ijms-24-05583-f001" orientation="portrait"><label>Figure 1</label><caption><p>Heatmap of normalized mRNA expression of 31 candidate genes according to molecular subtype of study population. Red color indicates higher expression level, while green color indicates lower expression level of mRNA expression.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-05583-g001.jpg"/></fig><fig position="float" id="ijms-24-05583-f002" orientation="portrait"><label>Figure 2</label><caption><p>Heatmap of correlation between 31 candidate genes in all study population. * <italic toggle="yes">p</italic>-value less than 0.05 estimated using Pearson correlation test. Red color indicates negative correlation (&#8722;1); blue color indicates positive correlation (+1); and the color intensity represents the strength of correlation.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-05583-g002.jpg"/></fig><fig position="float" id="ijms-24-05583-f003" orientation="portrait"><label>Figure 3</label><caption><p>Hierarchical clustering results of the target genes. (<bold>A</bold>) Optimal number of clusters estimated according to silhouette index. (<bold>B</bold>) Dendrogram of hierarchical clustering results of 31 target genes. (<bold>C</bold>) Cluster plot of target genes using the optimal number of clusters.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-05583-g003.jpg"/></fig><fig position="float" id="ijms-24-05583-f004" orientation="portrait"><label>Figure 4</label><caption><p>Kaplan&#8211;Meier plot for progression-free survival (PFS) according to risk estimation subgroup of two gene cluster determined using hierarchical clustering analysis. Red solid line indicates high-risk subgroup, and blue solid line indicates low-risk group. <italic toggle="yes">p</italic>-value is estimated using log-rank test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-05583-g004.jpg"/></fig><fig position="float" id="ijms-24-05583-f005" orientation="portrait"><label>Figure 5</label><caption><p>Kaplan&#8211;Meier plot for PFS according to risk estimation subgroup of gene cluster 1 in different lymph node (LN) invasion status. Red solid line indicates high-risk subgroup, and blue solid line indicates low-risk group. <italic toggle="yes">p</italic>-value is estimated using log-rank test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-05583-g005.jpg"/></fig><fig position="float" id="ijms-24-05583-f006" orientation="portrait"><label>Figure 6</label><caption><p>Kaplan&#8211;Meier plot for PFS according to risk estimation subgroup of gene cluster 1 in different treatment subgroup. Red solid line indicates high-risk subgroup, and blue solid line indicates low-risk group. <italic toggle="yes">p</italic>-value is estimated using log-rank test.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="ijms-24-05583-g006.jpg"/></fig><table-wrap position="float" id="ijms-24-05583-t001" orientation="portrait"><object-id pub-id-type="pii">ijms-24-05583-t001_Table 1</object-id><label>Table 1</label><caption><p>Baseline characteristics of study population (<italic toggle="yes">n</italic> = 486).</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Characteristics</th><th align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Overall</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Diagnosis age (years), mean &#177; SD</td><td align="center" valign="middle" rowspan="1" colspan="1">55.9 &#177; 12.4</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;Age group &#8805; 50 years</td><td align="center" valign="middle" rowspan="1" colspan="1">329 (68%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;Age group &lt; 50 years</td><td align="center" valign="middle" rowspan="1" colspan="1">157 (32%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Subtypes</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;Triple negative breast cancer (TNBC)</td><td align="center" valign="middle" rowspan="1" colspan="1">106 (22%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;Luminal A</td><td align="center" valign="middle" rowspan="1" colspan="1">224 (46.1%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;Luminal B</td><td align="center" valign="middle" rowspan="1" colspan="1">116 (23.9%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;HER2 type</td><td align="center" valign="middle" rowspan="1" colspan="1">40 (8.2%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Pathological stage</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;Stage I</td><td align="center" valign="middle" rowspan="1" colspan="1">87 (18%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;Stage II</td><td align="center" valign="middle" rowspan="1" colspan="1">300 (62%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;Stage III</td><td align="center" valign="middle" rowspan="1" colspan="1">99 (20%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;&#8195;IIIA</td><td align="center" valign="middle" rowspan="1" colspan="1">70 (14.4%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;&#8195;IIIB</td><td align="center" valign="middle" rowspan="1" colspan="1">6 (1.2%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;&#8195;IIIC</td><td align="center" valign="middle" rowspan="1" colspan="1">23 (4.7%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;Stage IV</td><td align="center" valign="middle" rowspan="1" colspan="1">0 (0%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Tumor size</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;T1 (&lt;2 cm)</td><td align="center" valign="middle" rowspan="1" colspan="1">144 (29.6%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;T2 (2 cm&#8211;5 cm)</td><td align="center" valign="middle" rowspan="1" colspan="1">303 (62.3%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;T3 (&gt;5 cm)</td><td align="center" valign="middle" rowspan="1" colspan="1">32 (6.6%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;T4 (direct to chest wall or skin)</td><td align="center" valign="middle" rowspan="1" colspan="1">7 (1.4%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Lymph node status</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;Non-lymph node invasion (LN0)</td><td align="center" valign="middle" rowspan="1" colspan="1">225 (46%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;Lymph node invasion (LN+)</td><td align="center" valign="middle" rowspan="1" colspan="1">261 (54%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;&#8195;N1 (1&#8211;3)</td><td align="center" valign="middle" rowspan="1" colspan="1">178 (36.6%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;&#8195;N2 (4&#8211;9)</td><td align="center" valign="middle" rowspan="1" colspan="1">59 (12.1%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#8195;&#8195;&#8195;N3 (&#8805;10)</td><td align="center" valign="middle" rowspan="1" colspan="1">24 (4.9%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Treatment</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;Radiotherapy (RT)</td><td align="center" valign="middle" rowspan="1" colspan="1">305 (63%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;Chemotherapy (CT)</td><td align="center" valign="middle" rowspan="1" colspan="1">386 (79%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Treatment subgroup</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;RT alone</td><td align="center" valign="middle" rowspan="1" colspan="1">52 (10.7%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;CT alone</td><td align="center" valign="middle" rowspan="1" colspan="1">133 (27.4%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;Chemotherapy + Radiotherapy</td><td align="center" valign="middle" rowspan="1" colspan="1">253 (52%)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Survival outcome</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">&#160;&#160;&#160;Died </td><td align="center" valign="middle" rowspan="1" colspan="1">29 (6%)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#160;&#160;&#160;Disease progressed</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">45 (9.3%)</td></tr></tbody></table><table-wrap-foot><fn><p>SD, standard deviation.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-24-05583-t002" orientation="portrait"><object-id pub-id-type="pii">ijms-24-05583-t002_Table 2</object-id><label>Table 2</label><caption><p>mRNA expression of 31 candidate genes among study population.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Genes</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">mRNA Expression</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Genes</th><th align="left" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">mRNA Expression</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">DNMT1</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">1.75 (&#8722;1.75, 6.11)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM2</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;1.53 (&#8722;8.84, 2.85)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">DNMT2</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;2.06 (&#8722;8.62, 5.47)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM4</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">0.53 (&#8722;7.29, 6.63)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">DNMT3A</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">1.96 (&#8722;1.48, 6.86)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM5</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;2.83 (&#8722;11.00, 3.04)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">DNMT3B</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">2.19 (&#8722;2.45, 7.70)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM6</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;0.13 (&#8722;4.58, 6.60)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">DNMT3L</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;3.12 (&#8722;3.12, 31.38)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM7</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">-1.86 (-1.86, 6.63)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">HDAC1</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">0.96 (&#8722;5.19, 4.74)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM8</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;2.58 (&#8722;9.36, 3.47)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">HDAC2</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">1.38 (&#8722;4.16, 10.61)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM9</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;14.32 (&#8722;14.32, 56.65)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">HDAC3</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">0.17 (&#8722;6.33, 5.73)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRMT1</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">0.97 (&#8722;2.07, 4.77)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM1</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">0.34 (&#8722;4.65, 4.93)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRMT10</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;1.51 (&#8722;8.33, 2.63)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM10</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;0.38 (&#8722;4.63, 3.37)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRMT2</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;1.14 (&#8722;4.80, 7.08)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM11</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;1.70 (&#8722;6.01, 2.43)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRMT3</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">0.80 (&#8722;5.64, 7.34)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM12</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">1.11 (&#8722;2.13, 7.80)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRMT5</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">0.60 (&#8722;5.05, 8.60)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM13</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;2.24 (&#8722;2.24, 21.56)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRMT6</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">0.66 (&#8722;6.83, 4.13)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM14</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;5.16 (&#8722;5.16, 10.82)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRMT7</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;0.001 (&#8722;3.79, 6.10)</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM15</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">0.50 (&#8722;3.15, 4.44)</td><td align="left" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRMT8</italic>
</td><td align="left" valign="middle" rowspan="1" colspan="1">&#8722;0.76 (&#8722;1.64, 14.55)</td></tr><tr><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">PRDM16</italic>
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;2.80 (&#8722;6.56, 2.62)</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="left" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr></tbody></table><table-wrap-foot><fn><p>All mRNA expressions were summarized using median and range.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="ijms-24-05583-t003" orientation="portrait"><object-id pub-id-type="pii">ijms-24-05583-t003_Table 3</object-id><label>Table 3</label><caption><p>mRNA expression of target genes according to risk estimation subgroup determined using GC1.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Genes</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Gene Cluster 1</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">
<italic toggle="yes">p</italic>
</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Low-Risk (<italic toggle="yes">n</italic> = 389)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">High-Risk (<italic toggle="yes">n</italic> = 97)</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">Gene cluster 1 included</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td><td align="center" valign="middle" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">DNMT1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1.59 (&#8722;1.75, 6.11)</td><td align="center" valign="middle" rowspan="1" colspan="1">2.39 (&#8722;0.68, 5.77)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">DNMT2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;2.37 (&#8722;8.62, 3.27)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.01 (&#8722;7.78, 5.47)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">DNMT3A</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1.74 (&#8722;1.48, 5.55)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.15 (&#8722;0.68, 6.86)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">DNMT3B</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">1.71 (&#8722;2.45, 7.31)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.64 (0.26, 7.70)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">DNMT3L</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;3.12 (&#8722;3.12, 10.90)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;3.12 (&#8722;3.12, 31.38)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">HDAC1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.89 (&#8722;5.19, 4.74)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.22 (&#8722;0.81, 3.89)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">HDAC2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.77 (&#8722;4.16, 8.34)</td><td align="center" valign="middle" rowspan="1" colspan="1">4.61 (&#8722;1.65, 10.61)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.076</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">HDAC3</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.11 (&#8722;6.33, 5.73)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.55 (&#8722;3.36, 4.82)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM7</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;1.86 (&#8722;1.86, 6.63)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;1.86 (&#8722;1.86, 5.33)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM9</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;14.32 (&#8722;14.32, 7.42)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;14.32 (&#8722;14.32, 56.65)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM12</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.94 (&#8722;2.13, 7.80)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.90 (&#8722;2.13, 6.70)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM13</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;2.24 (&#8722;2.24, 13.99)</td><td align="center" valign="middle" rowspan="1" colspan="1">3.12 (&#8722;2.24, 21.56)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.373</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM14</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;5.16 (&#8722;5.16, 10.82)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;5.16 (&#8722;5.16, 2.22)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRDM15</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.35 (&#8722;3.15, 3.16)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.35 (&#8722;1.35, 4.44)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRMT1</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.72 (&#8722;2.07, 4.47)</td><td align="center" valign="middle" rowspan="1" colspan="1">1.81 (&#8722;1.95, 4.77)</td><td align="center" valign="middle" rowspan="1" colspan="1">&lt;0.001</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRMT2</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;1.30 (&#8722;4.80, 3.34)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.25 (&#8722;3.32, 7.08)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.077</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRMT5</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.67 (&#8722;5.05, 5.48)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.33 (&#8722;3.67, 8.60)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.229</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRMT6</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.66 (&#8722;6.83, 4.13)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.63 (&#8722;3.88, 3.37)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.308</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">
<italic toggle="yes">PRMT7</italic>
</td><td align="center" valign="middle" rowspan="1" colspan="1">0.002 (&#8722;3.75, 6.10)</td><td align="center" valign="middle" rowspan="1" colspan="1">&#8722;0.14 (&#8722;3.79, 3.80)</td><td align="center" valign="middle" rowspan="1" colspan="1">0.011</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
<italic toggle="yes">PRMT8</italic>
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.68 (&#8722;1.64, 14.55)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8722;0.92 (&#8722;1.64, 10.46)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;0.001</td></tr></tbody></table><table-wrap-foot><fn><p>All mRNA expressions were summarized using median and range. <italic toggle="yes">p</italic>-value is estimated using Wilcoxon rank-sum test.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>